1
Certolizumab is reduced in Crohn's disease relative to the efficacy observed with adalimumab [24, 25], which suggests that Fc-mediated effector functions may be important. Binding of mAbs to FcRn affects clearance, so a similarity assessment of biosimilars should also include sensitive methods to assess binding to FcRn. ABP 501 was shown to have similar binding to FcRn as compared with adalimumab.
1
Manuscript.Compliance with Ethical Standards Amgen Inc. conducted and funded all analyses. Amgen Inc. also provided funding for medical writing and editorial support to MedVal Scientific Information Services, LLC, Skillman, NJ, USA. This article does not contain any studies with human participants or animals performed by any of the authors. This paper was prepared according to the ICMJE Uniform Re